Delivery Order 75N93021D00010-75N93024F00001

Award Date 7/1/24
Potential Completion Date 7/24/25
Potential Value $498K
Ultimate Awardee
Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Birmingham, AL 35205, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Cost Plus Fixed Fee federal delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Southern Research Institute, a non-profit research organization. The $249,997 contract is for the identification of anti-HIV lead compounds as part of NIAID's in vitro testing resource for HIV therapeutics and topical microbicides. Southern Research Institute, which holds multiple federal indefinite...
This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit organization. The contract, valued at $275,547.00, is a delivery order under a larger Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle for providing preclinical services related to the development of HIV therapeutics and topical microbicides. The work to be performed under...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Southern Research Institute, a non-profit research organization. The $257,889.11 cost-plus-fixed-fee contract is for the identification of anti-HIV lead compounds, which is part of NIAID's "In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides" program. The contract has no set-aside designation and is a...
This $537,319.27 federal delivery order contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The contract supports the TRANSFER AND VALIDATION OF BIOANALYTICAL METHOD FOR DETECTION OF CABOTEGRAVIR IN RAT PLASMA under NIAID's Comprehensive Resources for HIV Microbicides and Biomedical Prevention program. This work is being performed as a task order under...
This is a cost-plus-fixed-fee delivery order awarded to Southern Research Institute by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services (HHS). The $404,140 contract is to conduct hit-to-lead progression studies on interventional agents for the identification of anti-HIV lead compounds under the agency's Preclinical Services for HIV Therapeutics master IDIQ contract vehicle. The contract has no set-aside...
This is a cost-plus-fixed-fee delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit organization based in Birmingham, Alabama. The $99,998.00 contract requires Southern Research to acquire and store chemical compound libraries, and conduct high-throughput screening to identify and characterize at least one agent that can block HIV...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit organization. The $684,610.00 contract is for the identification of anti-HIV therapeutics and topical microbicides, which falls under NIAID's "In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides" major program. The contract has a...
This federal contract award, valued at $499,879.67, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit research organization. The contract is for the identification of lead compounds to inhibit HIV, as part of NIAID's broader "In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides" program. The contract is a Delivery Order...
This is a $749,989.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit organization based in Birmingham, Alabama. The contract is for a 500,000 compound screen to identify inhibitors of Gag processing, a key step in the life cycle of the HIV virus. This work supports NIAID's in vitro testing resource for HIV...
This is a Cost Plus Fixed Fee delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit organization. The contract, which has a ceiling value of $516,234.16, is for the identification of anti-HIV therapeutics and topical microbicides. It falls under NIAID's In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides program. The contract...

This is a $498,476.00 federal Delivery Order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Southern Research Institute, a non-profit research organization. The contract is for a pharmacokinetics study of the long-acting HIV therapeutic drug candidate Telacebec (Q203) in Sprague Dawley rats.

This Delivery Order is part of a larger Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle titled "Preclinical Services for HIV Therapeutics" that Southern Research holds with NIAID. Task orders under this IDIQ fund various preclinical drug development activities such as hit-to-lead compound progression, assay development, animal model creation, and efficacy evaluations for emerging antivirals. The contract does not have a set-aside designation.

Generated 12/10/24, 2:23 PM